The Independent
UK · 1 hrs ago
✦ 72◉ Centre
Daily pill almost doubles survival time for pancreatic cancer patients in new trial
72Quality
0Ratings
0Comments
AI Analysis
Quality 72/100
Partisan intensity 35/100
ObjectivePartisan
◉ Centre ✓ Fair headline
A new daily pill called daraxonrasib has shown promising results in clinical trials for pancreatic cancer patients, with researchers describing it as potentially transformative for treatment of the disease.
Daily pill almost doubles survival time for pancreatic cancer patients in new trial
Daraxonrasib has been hailed as ‘landscape-changing’ for people with the disease
Discussion 0 comments
Sort:
?
No comments yet — be the first to start the discussion!